{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:39:51Z","timestamp":1792237191985,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1127,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1124\/dmd.121.000595","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T16:21:30Z","timestamp":1633710090000},"page":"1109-1117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers"],"prefix":"10.1016","volume":"49","author":[{"given":"Maciej J.","family":"Zamek-Gliszczynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kenworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bershas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian I.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennypher","family":"Mudunuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill L.","family":"Pirhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl M.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy M.T.J.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Allinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"O\u2019Connor-Semmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000595_bib1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Al-Dury","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.121.000595_bib2","doi-asserted-by":"crossref","first-page":"G443","DOI":"10.1152\/ajpgi.00194.2001","article-title":"The proximal colonic motor response to rectal mechanical and chemical stimulation","volume":"282","author":"Bampton","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.121.000595_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000595_bib4","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1124\/dmd.108.021311","article-title":"Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling","volume":"36","author":"Barter","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000595_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00125-011-2382-3","article-title":"Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study","volume":"55","author":"Beysen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1124\/dmd.121.000595_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.121.000595_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000595_bib8","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.3390\/ijms16036432","article-title":"Primary biliary cirrhosis is a generalized autoimmune epithelitis","volume":"16","author":"Gao","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.121.000595_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/MEG.0000000000000223","article-title":"Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis","volume":"26","author":"Gotthardt","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.121.000595_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000595_bib11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1124\/dmd.119.088344","article-title":"An innovative approach to characterize clinical ADME pharmacokinetics of the inhaled drug Nemiralisib using an intravenous microtracer combined with an inhaled dose and an oral radiolabel dose in healthy male subjects","volume":"47","author":"Harrell","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000595_bib12","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1016\/S0168-8278(15)31349-0","article-title":"P1152: a comparative study of pruritus in PBC cohorts from UK, USA and Italy","volume":"62","author":"Hegade","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.121.000595_bib13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000595_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7861\/clinmedicine.15-4-351","article-title":"Drug treatment of pruritus in liver diseases","volume":"15","author":"Hegade","year":"2015","journal-title":"Clin Med (Lond)"},{"key":"10.1124\/dmd.121.000595_bib15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.121.000595_bib16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/liv.14069","article-title":"Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus","volume":"39","author":"Hegade","year":"2019","journal-title":"Liver Int"},{"key":"10.1124\/dmd.121.000595_bib17","unstructured":"ICRP (1992) Radiological Protection in Biomedical Research. ICRP Publication 62."},{"key":"10.1124\/dmd.121.000595_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpdd.576","article-title":"Safety, tolerability, pharmacokinetic and pharmacodynamic evaluations following single oral doses of GSK2330672 in healthy Japanese volunteers","volume":"8","author":"Ino","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.121.000595_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jfma.2016.05.006","article-title":"Quality of life among patients suffering from cholestatic liver disease-induced pruritus: a systematic review","volume":"115","author":"Jin","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1124\/dmd.121.000595_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.16143","article-title":"Review article: elobixibat: a novel treatment for chronic constipation","volume":"53","author":"Khanna","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.121.000595_bib20a","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.2042-7158.1997.tb06084.x","article-title":"Human jejunal effective permeability and its correlation with preclinical drug absorption models","volume":"49","author":"Lennern\u00e4s","year":"1997","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.121.000595_bib21","unstructured":"Levy C, Kendrick S, Bowlus CL, Tanaka A, Jones D, Kremer AE, Mayo MJ, Haque N, Zhang G, McLaughlin M, et al. (2020) GLIMMER Trial - a randomized double-blind placebo-controlled study of linerixibat, an inhibitor of the ileal bile acid transporter, in the treatment of cholestatic pruritus in primary biliary cholangitis (PBC), in: AASLD."},{"key":"10.1124\/dmd.121.000595_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1124\/dmd.121.000595_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/dom.12656","article-title":"Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin","volume":"18","author":"Nunez","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.121.000595_bib24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000595_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 7","key":"10.1124\/dmd.121.000595_bib26","first-page":"S23","article-title":"Importance of hepatic transporters in clinical disposition of drugs and their metabolites","volume":"56","author":"Patel","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000595_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdd.661","article-title":"Human radiolabeled mass balance studies: objectives, utilities and limitations","volume":"30","author":"Penner","year":"2009","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.121.000595_bib28","doi-asserted-by":"crossref","first-page":"744.e1","DOI":"10.1016\/j.amjmed.2017.01.037","article-title":"Management of pruritus in primary biliary cholangitis: a narrative review","volume":"130","author":"Trivedi","year":"2017","journal-title":"Am J Med"},{"key":"10.1124\/dmd.121.000595_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14740338.2021.1915984","article-title":"Safety considerations for the management of cholestatic itch","volume":"20","author":"Trivella","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/dmd.121.000595_bib30","series-title":"Clinical Drug Interaction Studies \u2014 Cytochrome","author":"US","year":"2020"},{"key":"10.1124\/dmd.121.000595_bib31","unstructured":"US FDA (2020b) Safety testing of drug metabolites guidance for industry."},{"key":"10.1124\/dmd.121.000595_bib32","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1021\/jm400459m","article-title":"Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes","volume":"56","author":"Wu","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.121.000595_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:23:56Z","timestamp":1739957036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624078218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0090955624078218"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000595","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}